News
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
Media
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
Publications
All Journals
For Authors
Tumor Board
Events
Frontline Forum
CME/CE
Resources
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Subscribe
Print Subscription
eNewsletter

logo
Spotlight
Around the Practice
Between the Lines
Contemporary Concepts
Journal
OncView
Podcasts
Readout 360
2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
CancerNetwork® Inaugural Face-Off
Contemporary Concepts in Hematologic Oncology
Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer
Clinical
Acute Myeloid Leukemia
Brain Cancer
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Gynecologic Cancer
Hematology
Leukemia
Lung Cancer
Lymphoma
Pediatric Cancers
Skin Cancer
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
All Journals
For Authors
Tumor Board
Frontline Forum
CME/CE
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Print Subscription
eNewsletter
Advertisement
Breast Cancer
| Kidney Cancer
| Leukemia
| Lymphoma
| Multiple Myeloma
| Non-Small Cell Lung Cancer (NSCLC)
| Small Cell Lung Cancer (SCLC)
| Adverse Effects
| Biomarkers
| Bladder Cancer
| Brain Cancer
| Cervical Cancer
| Colorectal Cancer
| Endometrial Cancer
| Esophageal Cancer
| Gastrointestinal Cancer
| Genitourinary Cancers
| Gynecologic Cancers
| Head & Neck Cancer
| Hematology
| Hormone-related Cancers
| Immunotherapy
| Infection
| Liver Cancer
| Lung Cancer
| Mesothelioma
| Neuroendocrine Tumors
| Oncology
| Ovarian Cancer
| Ovarian Cancer Clincal Consult
| Pancreatic Cancer
| Pediatric Cancers
| Prostate Cancer
| Radiation Oncology
| Sarcoma
| Screening
| Skin Cancer & Melanoma
| Surgery
| Thoracic Malignancies
| Thyroid Cancer
View All >>
  • Adverse Effects
  • Biomarkers
  • Bladder Cancer
  • Brain Cancer
  • Breast Cancer
  • Cervical Cancer
  • Colorectal Cancer
  • Endometrial Cancer
  • Esophageal Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancers
  • Gynecologic Cancers
  • Head & Neck Cancer
  • Hematology
  • Hormone-related Cancers
  • Immunotherapy
  • Infection
  • Kidney Cancer
  • Leukemia
  • Liver Cancer
  • Lung Cancer
  • Lymphoma
  • Mesothelioma
  • Multiple Myeloma
  • Neuroendocrine Tumors
  • Non-Small Cell Lung Cancer (NSCLC)
  • Oncology
  • Ovarian Cancer
  • Ovarian Cancer Clincal Consult
  • Pancreatic Cancer
  • Pediatric Cancers
  • Prostate Cancer
  • Radiation Oncology
  • Sarcoma
  • Screening
  • Skin Cancer & Melanoma
  • Small Cell Lung Cancer (SCLC)
  • Surgery
  • Thoracic Malignancies
  • Thyroid Cancer

SPOTLIGHT -

Around the Practice
| Between the Lines
| Contemporary Concepts
| Journal
| OncView
| Podcasts
| Readout 360
| 2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
| CancerNetwork® Inaugural Face-Off
| Contemporary Concepts in Hematologic Oncology
| Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
| Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer

AIDS-related Kaposi's Sarcoma: Options for Today and Tomorrow

Jun 2, 1996
Bijan Safai, MD
OncologyONCOLOGY Vol 10 No 6
Volume 10
Issue 6

Prior to 1981, Kaposi sarcoma (KS) was considered a rare human cancer occurring primarily among elderly Italian and Jewish men of eastern European ancestry. I wrote a review of KS research and clinical experiences that appeared in CA: A

Prior to 1981, Kaposi sarcoma (KS) was considered a rare human cancer occurring primarily among elderly Italian and Jewish men of eastern European ancestry. I wrote a review of KS research and clinical experiences that appeared in CA: A Cancer Journal for Clinicians. Publication of this article in January 1981 coincided with a dramatic upsurge in the number of cases of KS in young homosexual males reported to the Centers for Disease Control. The general lack of information about this disease was readily apparent when, upon publication of this article, my office was inundated with calls from physicians requesting additional information on this disease. Later on it was recognized that KS among young homosexual men was actually part of the clinical syndrome seen in the epidemic of acquired immune deficiency syndrome (AIDS).

The body of clinical experience with AIDS-related KS has grown significantly over the past 15 years. This experience has led to a greater understanding of the pathogenesis of KS in general, and angiogenesis and tumor growth factors in particular, and to the establishment of protocols for treating patients with AIDS-related KS. Now, physicians can usually diagnose this disease on a clinical basis, and pathologists can diagnose it with certainty on histologic grounds.

The purpose of this symposium was to review our experience with KS in patients with AIDS and to provide an update on KS epidemiology, pathology, and clinical presentation in AIDS patients. Current treatment options were discussed, as well as treatment modalities that are expected to be available in the near future.

The Epidemiologic Scope of Kaposi's Sarcoma

Worldwide, there are four clinical presentations of KS--the classic form, the African form, the form observed in transplant patients who are immunocompromised as a result of immunosuppressive drug therapy, and the AIDS form. Dr. Haverkos discusses in detail differences in the epidemiology and clinical presentation of these four forms of KS. Data suggest that the cause of AIDS-related KS is multifactorial. In addition to HIV infection, it has been hypothesized that necessary or enhancing cofactors associated with the development of this form of KS may include a genetic predisposition, the use of nitrite inhalants, a second sexually transmitted agent, or a fecal/oral agent. Dr. Haverkos supports this hypothesis using comprehensive epidemiologic data from the Centers for Disease Control and his own extensive research.

Clinical Manifestations of Kaposi's Sarcoma

In my presentation I discuss the clinical manifestations of KS. We have proposed that the etiologic factor responsible for KS is immune dysregulation, rather than immune deficiency. Epidemiologic data further suggest that the homosexual life-style contributes to conditions necessary for the development of this form of KS. The sexually transmissible cytomegalovirus and human papillomaviruses have been implicated in particular. Also implicated are the potentially mutagenic drugs, such as nitrite inhalants, that are frequently abused by AIDS patients prior to their becoming ill.

Current Theraputic Regimens for Karposi's Sarcoma

Treatment options available to patients with AIDS-related KS have not advanced significantly over the past decade. Radiation therapy, chemotherapy, and the use of biologic response modifiers continue as the standard treatment modalities. The efficacy of these treatment options is expertly reviewed by Dr. Abrams, who also discusses strategies for ameliorating potential side effects associated with them. Also discussed are promising new drugs, including inhibitors of viral proteins and antiangiogenesis agents, which, when coupled with new drug delivery systems, may more effectively target KS lesions and thus lessen dose-limiting side effects.

Current Studies on the Use of Liposomal Daunorubicin in Karposi's Sarcoma

Dr. Chew continues with a discussion of the pharmacokinetics of agents used in the treatment of AIDS-related KS accompanied by cutaneous disease with nodular lesions. In addition to disfigurement and skin ulcerations, extensive cutaneous disease can cause serious morbidity. More than 50% of patients with KS have oral cavity or gastrointestinal tract involvement that may lead to gastrointestinal hemorrhage; pulmonary involvement is not uncommon. Clinical studies suggest that the liposomal formulation of daunorubicin is an effective palliative agent for these patients and is associated with minimal toxicity. Encapsulation of daunorubicin also allows for targeting delivery of the drug to tumor cells without destroying surrounding tissue. Although not curative for KS, it has produced a response rate of 67% and the duration of these responses averages more than 100 days.

New Developments: A Look to the Future

Studies of the pathogenesis of KS contribute to a broader understanding of tumor biology in general and angiogenesis in particular. Dr. Gallo discusses studies that strongly suggest that the triggering mechanisms responsible for the development of early KS in HIV-related forms of the disease are the release of Tat from acutely infected T-cells and HIV-associated dysfunction in immune regulation, leading to an increase in inflammatory cytokine levels. Dr. Gallo also explains how activated spindle cells appear to provide a self-perpetuating, autocrine-supported mechanism for further development of the hyperplastic lesions and, in more advanced stages, neoplasms associated with KS.

Articles in this issue

AIDS-related Kaposi's Sarcoma: Options for Today and Tomorrow
Clinical Manifestations of Kaposi's Sarcoma
New Developments: A Look to the Future
The Epidemiologic Scope of Kaposi's Sarcoma
Pharmacology of Liposomal Daunorubicin and Its Use in Kaposi's Sarcoma
Current Therapeutic Options for Kaposi's Sarcoma
Discussion
Medical College of Wisconsin Researchers Seeking Ways to Prevent Pesticide-Induced Cancer in Wisconsin Farm Families
Comments on Bone Marrow Transplantation for Multiple Myeloma
New Aromatase Inhibitor Compared With Megestrol in Advanced Breast Cancer
Medicine as Business May Mean More Ethical Challenges for Physicians
US Public Health Service Guidelines for Testing and Counseling Blood and Plasma Donors for HIV-1 Antigen
Chemotherapy Plus Radiotherapy Superior to Radiotherapy Alone for Some Inoperable Head and Neck Cancers
DaunoXome Data Presented at International Cancer Meeting
NCI Reports Improvement in Breast Cancer Death Rate
Related Videos
Data from a ctDNA analysis of the phase 3 INTRIGUE study indicate that KIT mutational status may be associated with response to certain Tyrosine kinase inhibitors in GIST, according to an expert from the Yale Cancer Center in New Haven, Massachusetts.
Related Content

Balstilimab Combo Yields Survival Benefit in Soft Tissue Sarcoma

June 6th 2023

Aldoxorubicin Shows Promise in Advanced Soft-Tissue Sarcoma

July 22nd 2017

Nirogacestat Yields Significant Pain Reduction in Desmoid Tumor Population

June 4th 2023

Milademetan Does Not Improve Survival Vs Trabectedin in Liposarcoma

May 24th 2023

Continuous Doxorubicin Does Not Improve Efficacy in Soft Tissue Sarcoma

May 19th 2023

Trabectedin/Radiation Fails to Yield Robust Responses in Myxoid Liposarcoma

May 14th 2023

Balstilimab Combo Yields Survival Benefit in Soft Tissue Sarcoma

June 6th 2023

Aldoxorubicin Shows Promise in Advanced Soft-Tissue Sarcoma

July 22nd 2017

Nirogacestat Yields Significant Pain Reduction in Desmoid Tumor Population

June 4th 2023

Milademetan Does Not Improve Survival Vs Trabectedin in Liposarcoma

May 24th 2023

Continuous Doxorubicin Does Not Improve Efficacy in Soft Tissue Sarcoma

May 19th 2023

Trabectedin/Radiation Fails to Yield Robust Responses in Myxoid Liposarcoma

May 14th 2023

Balstilimab Combo Yields Survival Benefit in Soft Tissue Sarcoma

June 6th 2023

Aldoxorubicin Shows Promise in Advanced Soft-Tissue Sarcoma

July 22nd 2017

Nirogacestat Yields Significant Pain Reduction in Desmoid Tumor Population

June 4th 2023

Milademetan Does Not Improve Survival Vs Trabectedin in Liposarcoma

May 24th 2023

Continuous Doxorubicin Does Not Improve Efficacy in Soft Tissue Sarcoma

May 19th 2023

Trabectedin/Radiation Fails to Yield Robust Responses in Myxoid Liposarcoma

May 14th 2023
Related Content

Most adverse effects in a phase 2 trial related to doxorubicin appear to be expected in the treatment of patients with soft tissue sarcoma.

Balstilimab Combo Yields Survival Benefit in Soft Tissue Sarcoma

June 6th 2023
Article

Most adverse effects in a phase 2 trial related to doxorubicin appear to be expected in the treatment of patients with soft tissue sarcoma.


Aldoxorubicin Shows Promise in Advanced Soft-Tissue Sarcoma

Aldoxorubicin Shows Promise in Advanced Soft-Tissue Sarcoma

July 22nd 2017
Podcast

In this interview we discuss the phase III trial of aldoxorubicin in patients with advanced soft-tissue sarcoma, which showed improved efficacy and reduced toxicity over doxorubicin.


Nirogacestat Yields Significant Pain Reduction Desmoid Tumor Population | Image Credit: © David A Litman - stock.adobe.com.

Nirogacestat Yields Significant Pain Reduction in Desmoid Tumor Population

June 4th 2023
Article

Nirogacestat also appears to improve progression-free survival compared with placebo among those with desmoid tumors in the phase 3 DeFi trial.


Milademetan Does Not Improve Survival Vs Trabectedin in Liposarcoma | Image Credit: © David A Litman - stock.adobe.com.

Milademetan Does Not Improve Survival Vs Trabectedin in Liposarcoma

May 24th 2023
Article

Manufacturers plan to halt further development of milademetan for liposarcoma following the publication of topline results from the phase 3 MANTRA trial.


A post hoc analysis indicates continuous intravenous infusion of doxorubicin did not yield additional benefit for patients with soft-tissue sarcoma compared with bolus delivery methods.

Continuous Doxorubicin Does Not Improve Efficacy in Soft Tissue Sarcoma

May 19th 2023
Article

A post hoc analysis indicates continuous intravenous infusion of doxorubicin does not yield additional benefit for patients with soft-tissue sarcoma compared with bolus delivery methods.


Findings from a phase 2 trial suggest that trabectedin plus radiotherapy is a tolerable treatment option in patients with myxoid liposarcoma despite yielding an unsatisfactory overall response rate.

Trabectedin/Radiation Fails to Yield Robust Responses in Myxoid Liposarcoma

May 14th 2023
Article

Findings from a phase 2 trial suggest that trabectedin plus radiotherapy is a tolerable treatment option in patients with myxoid liposarcoma despite yielding an unsatisfactory overall response rate.

About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.